Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation 
Syntheia Signs Definitive Agreement for Call Center Acquisition 
CORRECTING and REPLACING Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification 
Wells Fargo Scandal Drove Borrowers to Fintech Lenders, UC Davis Study Suggests Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics…
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics…
Recce Pharmaceuticals Announces Change of Director’s Interest Notices – James Graham
SYDNEY, Australia, June 28, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q),…
Recce Pharmaceuticals Announces Change of Director’s Interest Notices – James Graham
SYDNEY, Australia, June 28, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q),…
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day
Company views that results of comprehensive data analysis of TSHA-120 and development of disease progression…
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day
Company views that results of comprehensive data analysis of TSHA-120 and development of disease progression…
Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
Early data observed from NAVAL-1 in R/R EBV+ PTCL consistent with Phase 1b/2 clinical trial…
Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
Early data observed from NAVAL-1 in R/R EBV+ PTCL consistent with Phase 1b/2 clinical trial…
Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform
CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or…
Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform
CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or…
Avicanna Provides Corporate Update and Preliminary Q2 Results
TORONTO, June 28, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN)…
Avicanna Provides Corporate Update and Preliminary Q2 Results
TORONTO, June 28, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN)…
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical…
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical…
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
Topline data expected in July 2023 BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) —…
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
Topline data expected in July 2023 BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) —…
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
– Clinical data support safety and tolerability profile of FHD-286, a highly potent, – selective,…
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
– Clinical data support safety and tolerability profile of FHD-286, a highly potent, – selective,…
Breckenridge Distillery Launches New Limited Release Collectors Art Series With Artist Sandra Fettingis
For its Third Annual Collectors Art Series, Breckenridge Distillery Partners with Local Colorado Artist to…
Breckenridge Distillery Launches New Limited Release Collectors Art Series With Artist Sandra Fettingis
For its Third Annual Collectors Art Series, Breckenridge Distillery Partners with Local Colorado Artist to…